Cargando…
HDAC inhibitors as antifibrotic drugs in cardiac and pulmonary fibrosis
Fibrosis usually results from dysregulated wound repair and is characterized by excessive scar tissue. It is a complex process with unclear mechanisms. Accumulating evidence indicates that epigenetic alterations, including histone acetylation, play a pivotal role in this process. Histone acetylation...
Autores principales: | Lyu, Xing, Hu, Min, Peng, Jieting, Zhang, Xiangyu, Sanders, Yan Y |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6643173/ https://www.ncbi.nlm.nih.gov/pubmed/31367296 http://dx.doi.org/10.1177/2040622319862697 |
Ejemplares similares
-
Antifibrotic therapies to control cardiac fibrosis
por: Fan, Zhaobo, et al.
Publicado: (2016) -
Rhein, a novel Histone Deacetylase (HDAC) inhibitor with antifibrotic potency in human myocardial fibrosis
por: Barbosa, David Monteiro, et al.
Publicado: (2020) -
Antifibrotic therapy for idiopathic pulmonary fibrosis: time to treat
por: Maher, Toby M., et al.
Publicado: (2019) -
ANTIFIBROTIC THERAPY IN IDIOPATHIC PULMONARY FIBROSIS
por: Scullion, T., et al.
Publicado: (2017) -
Antifibrotic drugs for idiopathic pulmonary fibrosis: What we should know?
por: Hadda, Vijay, et al.
Publicado: (2020)